Clinical trial

A Study to Evaluate ALN-2232 in Participants With Obesity

NCT07463846

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2026-03-02

PhasePHASE1 / PHASE2

Study timeline

Study start (actual)2026-03-02Date precision: day

Registry last updated2026-09-16

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Obesityunresolved

Interventions

ALN-2232DRUG

PlaceboDRUG

TirzepatideDRUG · verified · RxNorm: tirzepatide

Sponsors & collaborators

Alnylam Pharmaceuticalslead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07463846 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.